-
2
-
-
84863707351
-
Cancer treatment and survivorship statistics, 2012
-
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 220-241
-
-
Siegel, R.1
DeSantis, C.2
Virgo, K.3
Stein, K.4
Mariotto, A.5
Smith, T.6
Cooper, D.7
Gansler, T.8
Lerro, C.9
Fedewa, S.10
Lin, C.11
Leach, C.12
Cannady, R.S.13
-
3
-
-
84924271853
-
Global cancer statistics, 2012
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
-
(2015)
CA Cancer J Clin
, vol.65
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
Ferlay, J.4
Lortet-Tieulent, J.5
Jemal, A.6
-
4
-
-
84858310285
-
Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years
-
van der Drift MA, Karim-Kos HE, Siesling S, Groen HJ, Wouters MW, Coebergh JW, de VE, Janssen-Heijnen ML: Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 2012;7:291-298.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 291-298
-
-
van der Drift, M.A.1
Karim-Kos, H.E.2
Siesling, S.3
Groen, H.J.4
Wouters, M.W.5
Coebergh, J.W.6
de, V.E.7
Janssen-Heijnen, M.L.8
-
5
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
Patnaik, A.7
Aggarwal, C.8
Gubens, M.9
Horn, L.10
Carcereny, E.11
Ahn, M.J.12
Felip, E.13
-
6
-
-
84936749833
-
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
-
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2015;33:2004-2012.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2004-2012
-
-
Gettinger, S.N.1
Horn, L.2
Gandhi, L.3
Spigel, D.R.4
Antonia, S.J.5
Rizvi, N.A.6
Powderly, J.D.7
Heist, R.S.8
Carvajal, R.D.9
Jackman, D.M.10
Sequist, L.V.11
Smith, D.C.12
Leming, P.13
-
7
-
-
84928605037
-
Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis
-
Jia M, Feng W, Kang S, Zhang Y, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W: Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis 2015;7:455-461.
-
(2015)
J Thorac Dis
, vol.7
, pp. 455-461
-
-
Jia, M.1
Feng, W.2
Kang, S.3
Zhang, Y.4
Shen, J.5
He, J.6
Jiang, L.7
Wang, W.8
Guo, Z.9
Peng, G.10
Chen, G.11
He, J.12
Liang, W.13
-
8
-
-
84975797039
-
Nivolumab approved for lung cancer
-
Nivolumab approved for lung cancer. Cancer Discov 2015;5:OF1.
-
(2015)
Cancer Discov
, vol.5
-
-
-
9
-
-
42549138499
-
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
-
Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008;8:351-360.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 351-360
-
-
Melief, C.J.1
van der Burg, S.H.2
-
10
-
-
52649163840
-
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
-
Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT: Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5220-5227
-
-
Al-Shibli, K.I.1
Donnem, T.2
Al-Saad, S.3
Persson, M.4
Bremnes, R.M.5
Busund, L.T.6
-
11
-
-
79953028602
-
The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer
-
Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT: The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011;6:824-833.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 824-833
-
-
Bremnes, R.M.1
Al-Shibli, K.2
Donnem, T.3
Sirera, R.4
Al-Saad, S.5
Andersen, S.6
Stenvold, H.7
Camps, C.8
Busund, L.T.9
-
12
-
-
84925852186
-
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissueresident memory T cells and a prognostic factor for survival in lung cancer patients
-
Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de M, V, Validire P, Besse B, Mami-Chouaib F: CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissueresident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015;194:3475-3486.
-
(2015)
J Immunol
, vol.194
, pp. 3475-3486
-
-
Djenidi, F.1
Adam, J.2
Goubar, A.3
Durgeau, A.4
Meurice, G.5
de Montpreville, V.6
Validire, P.7
Besse, B.8
Mami-Chouaib, F.9
-
13
-
-
84930650878
-
Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
-
Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, et al. Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21:2635-2643.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2635-2643
-
-
Donnem, T.1
Hald, S.M.2
Paulsen, E.E.3
Richardsen, E.4
Al-Saad, S.5
Kilvaer, T.K.6
Brustugun, O.T.7
Helland, A.8
Lund-Iversen, M.9
Poehl, M.10
Olsen, K.E.11
Ditzel, H.J.12
Hansen, O.13
-
14
-
-
31444439350
-
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
-
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H: Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-280.
-
(2006)
Br J Cancer
, vol.94
, pp. 275-280
-
-
Hiraoka, K.1
Miyamoto, M.2
Cho, Y.3
Suzuoki, M.4
Oshikiri, T.5
Nakakubo, Y.6
Itoh, T.7
Ohbuchi, T.8
Kondo, S.9
Katoh, H.10
-
15
-
-
84927173508
-
Objective measurement and clinical significance of TILs in non-small cell lung cancer
-
Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL: Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015;107.
-
(2015)
J Natl Cancer Inst
, pp. 107
-
-
Schalper, K.A.1
Brown, J.2
Carvajal-Hausdorf, D.3
McLaughlin, J.4
Velcheti, V.5
Syrigos, K.N.6
Herbst, R.S.7
Rimm, D.L.8
-
16
-
-
84891486289
-
Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients
-
Baba T, Shiota H, Kuroda K, Shigematsu Y, Ichiki Y, Uramoto H, Hanagiri T, Tanaka F: Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients. Int J Clin Oncol 2013;18:997-1004.
-
(2013)
Int J Clin Oncol
, vol.18
, pp. 997-1004
-
-
Baba, T.1
Shiota, H.2
Kuroda, K.3
Shigematsu, Y.4
Ichiki, Y.5
Uramoto, H.6
Hanagiri, T.7
Tanaka, F.8
-
17
-
-
84878203142
-
Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer
-
Hanagiri T, Shigematsu Y, Shinohara S, Takenaka M, Oka S, Chikaishi Y, Nagata Y, Baba T, Uramoto H, So T, Yamada S: Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer. Anticancer Res 2013;33:2123-2128.
-
(2013)
Anticancer Res
, vol.33
, pp. 2123-2128
-
-
Hanagiri, T.1
Shigematsu, Y.2
Shinohara, S.3
Takenaka, M.4
Oka, S.5
Chikaishi, Y.6
Nagata, Y.7
Baba, T.8
Uramoto, H.9
So, T.10
Yamada, S.11
-
18
-
-
84876414840
-
Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer
-
Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, Uramoto H, So T, Takenoyama M, Tanaka F: Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. J Surg Res 2013;181:e57-e63.
-
(2013)
J Surg Res
, vol.181
, pp. e57-e63
-
-
Hanagiri, T.1
Shigematsu, Y.2
Kuroda, K.3
Baba, T.4
Shiota, H.5
Ichiki, Y.6
Nagata, Y.7
Yasuda, M.8
Uramoto, H.9
So, T.10
Takenoyama, M.11
Tanaka, F.12
-
19
-
-
34547838409
-
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer
-
Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M: HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007;98:1424-1430.
-
(2007)
Cancer Sci
, vol.98
, pp. 1424-1430
-
-
Kikuchi, E.1
Yamazaki, K.2
Torigoe, T.3
Cho, Y.4
Miyamoto, M.5
Oizumi, S.6
Hommura, F.7
Dosaka-Akita, H.8
Nishimura, M.9
-
20
-
-
34948818207
-
Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer
-
Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM: Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007;58:267-274.
-
(2007)
Lung Cancer
, vol.58
, pp. 267-274
-
-
Yie, S.M.1
Yang, H.2
Ye, S.R.3
Li, K.4
Dong, D.D.5
Lin, X.M.6
-
21
-
-
57149140898
-
HLA-G-dependent suppressor cells: Diverse by nature, function, and significance
-
Carosella ED, HoWangYin KY, Favier B, LeMaoult J: HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum Immunol 2008;69:700-707.
-
(2008)
Hum Immunol
, vol.69
, pp. 700-707
-
-
Carosella, E.D.1
HoWangYin, K.Y.2
Favier, B.3
LeMaoult, J.4
-
22
-
-
0034529752
-
Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors
-
Lepin EJ, Bastin JM, Allan DS, Roncador G, Braud VM, Mason DY, van der Merwe PA, McMichael AJ, Bell JI, Powis SH, O'Callaghan CA: Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000;30:3552-3561.
-
(2000)
Eur J Immunol
, vol.30
, pp. 3552-3561
-
-
Lepin, E.J.1
Bastin, J.M.2
Allan, D.S.3
Roncador, G.4
Braud, V.M.5
Mason, D.Y.6
van der Merwe, P.A.7
McMichael, A.J.8
Bell, J.I.9
Powis, S.H.10
O'Callaghan, C.A.11
-
23
-
-
80755153769
-
HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer
-
Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ, Yan WH: HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer 2011;74:504-509.
-
(2011)
Lung Cancer
, vol.74
, pp. 504-509
-
-
Lin, A.1
Zhang, X.2
Ruan, Y.Y.3
Wang, Q.4
Zhou, W.J.5
Yan, W.H.6
-
25
-
-
77958085762
-
The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress
-
van Hall T., Oliveira CC, Joosten SA, OttenhoffTH: The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect 2010;12:910-918.
-
(2010)
Microbes Infect
, vol.12
, pp. 910-918
-
-
van Hall, T.1
Oliveira, C.C.2
Joosten, S.A.3
Ottenhoff, T.H.4
-
26
-
-
84902251245
-
Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy
-
van Esch EM, Tummers B, Baartmans V, Osse EM, Ter HN, Trietsch MD, Hellebrekers BW, Holleboom CA, Nagel HT, Tan LT, Fleuren GJ, van Poelgeest MI, van der Burg SH, Jordanova ES: Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer 2014;135:830-842.
-
(2014)
Int J Cancer
, vol.135
, pp. 830-842
-
-
van Esch, E.M.1
Tummers, B.2
Baartmans, V.3
Osse, E.M.4
Ter, H.N.5
Trietsch, M.D.6
Hellebrekers, B.W.7
Holleboom, C.A.8
Nagel, H.T.9
Tan, L.T.10
Fleuren, G.J.11
van Poelgeest, M.I.12
van der Burg, S.H.13
Jordanova, E.S.14
-
27
-
-
79960587042
-
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes
-
Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van HT: HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 2011;108:10656-10661.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 10656-10661
-
-
Gooden, M.1
Lampen, M.2
Jordanova, E.S.3
Leffers, N.4
Trimbos, J.B.5
van der Burg, S.H.6
Nijman, H.7
van, H.T.8
-
28
-
-
19844373387
-
Epidemiology of lung cancer: looking to the future
-
Alberg AJ, Brock MV, Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23:3175-3185.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3175-3185
-
-
Alberg, A.J.1
Brock, M.V.2
Samet, J.M.3
-
29
-
-
0030061067
-
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer
-
Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC: Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996;73:148-153.
-
(1996)
Br J Cancer
, vol.73
, pp. 148-153
-
-
Korkolopoulou, P.1
Kaklamanis, L.2
Pezzella, F.3
Harris, A.L.4
Gatter, K.C.5
-
30
-
-
77958181793
-
Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12, 509 cases in a Japanese Lung Cancer Registry study
-
Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y: Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12, 509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol 2010;5:1594-1601.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1594-1601
-
-
Sakurai, H.1
Asamura, H.2
Goya, T.3
Eguchi, K.4
Nakanishi, Y.5
Sawabata, N.6
Okumura, M.7
Miyaoka, E.8
Fujii, Y.9
-
31
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
Lee, W.7
Yuan, J.8
Wong, P.9
Ho, T.S.10
Miller, M.L.11
Rekhtman, N.12
Moreira, A.L.13
-
32
-
-
52049127030
-
Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens
-
Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M: Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun 2008;8:13.
-
(2008)
Cancer Immun
, vol.8
, pp. 13
-
-
Kikuchi, E.1
Yamazaki, K.2
Nakayama, E.3
Sato, S.4
Uenaka, A.5
Yamada, N.6
Oizumi, S.7
Dosaka-Akita, H.8
Nishimura, M.9
-
33
-
-
33646368439
-
Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
-
Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S: Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2006;55:891-899.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 891-899
-
-
Ramnath, N.1
Tan, D.2
Li, Q.3
Hylander, B.L.4
Bogner, P.5
Ryes, L.6
Ferrone, S.7
-
34
-
-
84928615785
-
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis
-
Pan ZK, Ye F, Wu X, An HX, Wu JX: Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 2015;7:462-470.
-
(2015)
J Thorac Dis
, vol.7
, pp. 462-470
-
-
Pan, Z.K.1
Ye, F.2
Wu, X.3
An, H.X.4
Wu, J.X.5
-
35
-
-
0032989465
-
Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences
-
Ulbrecht M, Couturier A, Martinozzi S, Pla M, Srivastava R, Peterson PA, Weiss EH: Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol 1999;29:537-547.
-
(1999)
Eur J Immunol
, vol.29
, pp. 537-547
-
-
Ulbrecht, M.1
Couturier, A.2
Martinozzi, S.3
Pla, M.4
Srivastava, R.5
Peterson, P.A.6
Weiss, E.H.7
-
36
-
-
22544466982
-
The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells
-
Guma M, Busch LK, Salazar-Fontana LI, Bellosillo B, Morte C, Garcia P, Lopez-Botet M: The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur J Immunol 2005;35:2071-2080.
-
(2005)
Eur J Immunol
, vol.35
, pp. 2071-2080
-
-
Guma, M.1
Busch, L.K.2
Salazar-Fontana, L.I.3
Bellosillo, B.4
Morte, C.5
Garcia, P.6
Lopez-Botet, M.7
-
37
-
-
78650666422
-
HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients
-
de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ: HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010;185:7452-7459.
-
(2010)
J Immunol
, vol.185
, pp. 7452-7459
-
-
de Kruijf, E.M.1
Sajet, A.2
van Nes, J.G.3
Natanov, R.4
Putter, H.5
Smit, V.T.6
Liefers, G.J.7
van den Elsen, P.J.8
van de Velde, C.J.9
Kuppen, P.J.10
-
38
-
-
84865620173
-
HLA-E expression in cervical adenocarcinomas: association with improved long-term survival
-
Spaans VM, Peters AA, Fleuren GJ, Jordanova ES: HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med 2012;10:184.
-
(2012)
J Transl Med
, vol.10
, pp. 184
-
-
Spaans, V.M.1
Peters, A.A.2
Fleuren, G.J.3
Jordanova, E.S.4
-
39
-
-
84862578622
-
HLA-E/beta2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression
-
Bossard C, Bezieau S, Matysiak-Budnik T, Volteau C, Laboisse CL, Jotereau F, Mosnier JF: HLA-E/beta2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer 2012;131:855-863.
-
(2012)
Int J Cancer
, vol.131
, pp. 855-863
-
-
Bossard, C.1
Bezieau, S.2
Matysiak-Budnik, T.3
Volteau, C.4
Laboisse, C.L.5
Jotereau, F.6
Mosnier, J.F.7
-
40
-
-
84928384439
-
Human Leukocyte Antigen (HLA)-E and HLA-F Expression in Gastric Cancer
-
Ishigami S, Arigami T, Okumura H, Uchikado Y, Kita Y, Kurahara H, Maemura K, Kijima Y, Ishihara Y, Sasaki K, Uenosono Y, Natsugoe S: Human Leukocyte Antigen (HLA)-E and HLA-F Expression in Gastric Cancer. Anticancer Res 2015;35:2279-2285.
-
(2015)
Anticancer Res
, vol.35
, pp. 2279-2285
-
-
Ishigami, S.1
Arigami, T.2
Okumura, H.3
Uchikado, Y.4
Kita, Y.5
Kurahara, H.6
Maemura, K.7
Kijima, Y.8
Ishihara, Y.9
Sasaki, K.10
Uenosono, Y.11
Natsugoe, S.12
-
41
-
-
84873343770
-
Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer
-
Zhen ZJ, Ling JY, Cai Y, Luo WB, He YJ: Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med Oncol 2013;30:482.
-
(2013)
Med Oncol
, vol.30
, pp. 482
-
-
Zhen, Z.J.1
Ling, J.Y.2
Cai, Y.3
Luo, W.B.4
He, Y.J.5
-
43
-
-
63349086603
-
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
-
Levy EM, Sycz G, Arriaga JM, Barrio MM, Von Euw EM, Morales SB, Gonzalez M, Mordoh J, Bianchini M: Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 2009;15:91-100.
-
(2009)
Innate Immun
, vol.15
, pp. 91-100
-
-
Levy, E.M.1
Sycz, G.2
Arriaga, J.M.3
Barrio, M.M.4
Von Euw, E.M.5
Morales, S.B.6
Gonzalez, M.7
Mordoh, J.8
Bianchini, M.9
-
44
-
-
33747793367
-
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells
-
Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N: Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006;177:3100-3107.
-
(2006)
J Immunol
, vol.177
, pp. 3100-3107
-
-
Derre, L.1
Corvaisier, M.2
Charreau, B.3
Moreau, A.4
Godefroy, E.5
Moreau-Aubry, A.6
Jotereau, F.7
Gervois, N.8
-
46
-
-
0032146173
-
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis
-
Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M: Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer 1998;34:1334-1340.
-
(1998)
Eur J Cancer
, vol.34
, pp. 1334-1340
-
-
Ruiter, D.J.1
Ferrier, C.M.2
van Muijen, G.N.3
Henzen-Logmans, S.C.4
Kennedy, S.5
Kramer, M.D.6
Nielsen, B.S.7
Schmitt, M.8
|